PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Volatility & Risk
PMV Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.25, indicating that its stock price is 525% more volatile than the S&P 500.
Earnings and Valuation
This table compares PMV Pharmaceuticals and Vivos Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PMV Pharmaceuticals | N/A | N/A | -$77.74 million | ($1.49) | -0.91 |
| Vivos Therapeutics | $17.44 million | 0.60 | -$21.17 million | ($2.07) | -0.37 |
Vivos Therapeutics has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for PMV Pharmaceuticals and Vivos Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PMV Pharmaceuticals | 1 | 0 | 0 | 1 | 2.50 |
| Vivos Therapeutics | 1 | 2 | 2 | 0 | 2.20 |
PMV Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 266.84%. Vivos Therapeutics has a consensus target price of $2.58, suggesting a potential upside of 239.91%. Given PMV Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe PMV Pharmaceuticals is more favorable than Vivos Therapeutics.
Profitability
This table compares PMV Pharmaceuticals and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PMV Pharmaceuticals | N/A | -59.07% | -54.19% |
| Vivos Therapeutics | -121.37% | -849.22% | -96.11% |
Insider and Institutional Ownership
90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
PMV Pharmaceuticals beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
